Theravance Biopharma Inc (TBPH)
9.61
-0.36
(-3.61%)
USD |
NASDAQ |
Nov 21, 16:00
Theravance Biopharma Debt to Equity Ratio: 0.00 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
September 30, 2024 | 0.00 |
June 30, 2024 | 0.00 |
March 31, 2024 | 0.00 |
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 0.00 |
September 30, 2022 | 0.00 |
June 30, 2022 | -1.786 |
March 31, 2022 | -1.768 |
December 31, 2021 | -1.820 |
September 30, 2021 | -1.903 |
June 30, 2021 | -2.029 |
March 31, 2021 | -1.645 |
December 31, 2020 | -2.038 |
September 30, 2020 | -2.337 |
June 30, 2020 | -2.974 |
March 31, 2020 | -3.799 |
December 31, 2019 | -2.033 |
September 30, 2019 | -2.496 |
June 30, 2019 | -3.319 |
Date | Value |
---|---|
March 31, 2019 | -4.016 |
December 31, 2018 | -8.807 |
September 30, 2018 | -16.70 |
June 30, 2018 | 6.522 |
March 31, 2018 | 3.533 |
December 31, 2017 | 1.943 |
September 30, 2017 | 1.214 |
June 30, 2017 | 0.9257 |
March 31, 2017 | 0.7584 |
December 31, 2016 | 0.6358 |
September 30, 2016 | 0.00 |
June 30, 2016 | 0.00 |
March 31, 2016 | 0.00 |
December 31, 2015 | 0.00 |
September 30, 2015 | 0.00 |
June 30, 2015 | 0.00 |
March 31, 2015 | 0.00 |
December 31, 2014 | 0.00 |
September 30, 2014 | 0.00 |
June 30, 2014 | 0.00 |
March 31, 2014 | 0.00 |
December 31, 2013 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-3.799
Minimum
Mar 2020
--
Maximum
Sep 2022
-1.207
Average
-1.707
Median
Debt to Equity Ratio Benchmarks
Corcept Therapeutics Inc | 0.00 |
Madrigal Pharmaceuticals Inc | 0.1507 |
Ionis Pharmaceuticals Inc | 1.930 |
Jazz Pharmaceuticals PLC | 1.465 |
NovaBay Pharmaceuticals Inc | 0.0476 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 356.10M |
Total Liabilities (Quarterly) | 170.45M |
Shareholders Equity (Quarterly) | 185.65M |
Current Ratio | 4.970 |